Clinical Trial Update: Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer. [NA]

View source ↗

Summary

Update on a clinical trial studying genetic predictors of response to Gemcitabine, Docetaxel, and Capecitabine in metastatic or unresectable pancreatic cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: University of Southern California | Conditions: Pancreatic Cancer | NA | Status: TERMINATED